分子靶向药物治疗结直肠癌研究进展
Progress on molecular targeted-drug in the treatment of colorectal carcinoma
摘要
分子靶向药物治疗是特异性针对肿瘤发生、发展、浸润与转移等环节的一种新的药物治疗方法。结直肠癌患者中特异性靶向肿瘤细胞药物的应用是近年研究的热点。现综述表皮生长因子受体(EGFR)抑制剂、环氧合酶(COX)-2抑制剂和血管内皮生长因子(VEGF)抑制剂等分子靶向药物在结直肠癌中的研究和临床应用。
出处
《国外医学（肿瘤学分册）》
2004年第10期791-794,共4页
Foreign Medical Sciences (Cancer Section)
参考文献24
-
1Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000.The global picture. Eur J Cancer,2001,37( Suppl 8) :S4-66.
-
2Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am,2002,16(5 ) :1041-1063.
-
3Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer,2003,2 (4) :246 -251.
-
4Cunningham D, Humblet Y, Siena S, et al. Cetuximab ( 225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EG FR) -positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol,2003, 22: 252(abstr 1012).
-
5Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol,2004,22 (7) :1201-1208.
-
6Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol, 2003,4(5 ) :393- 403.
-
7Vanhoefer U, Tewes M, Rojo F, et al. Phase Ⅰ study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 2004,22 (1) :175-184.
-
8Douglass EC. Development of ZD1839 in colorectal cancer. Semin Oncol, 2003,30 (3 Suppl6): 17-22.
-
9Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase Ⅰ trial. J Clin Oncol,2002,20(9) :2240-2250.
-
10Hidalgo M, Siu LL, Nemunaltis J, et al. Phase Ⅰ and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol,2001,19(13) :3267-3279.
-
1张朋,孙媛,姚媛媛,刘佳.白藜芦醇对女性生殖系统恶性肿瘤作用的研究进展[J].大连医科大学学报,2015,37(4):403-407. 被引量：4
-
2王惠兰,刘影,张晓茗,杜辉,杨素娟.大蒜素与顺铂单独及联合应用对子宫颈癌裸鼠移植瘤生长的影响[J].中华妇产科杂志,2006,41(8):566-567. 被引量：7
-
3牛新光,白兴禄.晚期癌症疼痛的药物治疗方法[J].肿瘤防治杂志,2000,7(5):560-560.
-
4孟宪颖,吕传鹤,王爱光.胃肠道间质瘤51例辅助检查及生存分析[J].中国误诊学杂志,2011,11(3):678-679. 被引量：3
-
5黄丽群.米非司酮治疗子宫肌瘤97例临床分析[J].右江民族医学院学报,2006,28(5):808-809.
-
6王天峰,林本耀.乳腺癌化疗：血液学毒性的处理[J].癌症康复,2005(5):18-19.
-
7王智霞.观察米非司酮保守治疗子宫肌瘤的临床疗效[J].临床医学,2012,32(7):76-77. 被引量：1
-
8刘小立.癌痛“三阶梯”以外的药物治疗方法[J].实用疼痛学杂志,2008,4(6):437-438. 被引量：2
-
9前列腺癌细胞如何对抗死亡[J].基础医学与临床,2006,26(9):983-983.
-
10陆舜.肺癌分子靶向治疗的现状与展望[J].肿瘤研究与临床,2004,16(1):1-3. 被引量：4
